Two-dose strategies for human papillomavirus vaccination: How well do they need to protect?

Vaccine

Volumn 32, Issue 26, 2014, Pages 3237-3242

  Jit, Mark ^a,b   Choi, Yoon Hong ^a   Laprise, Jean François ^c   Boily, Marie Claude ^d   Drolet, Mélanie ^c,e   Brisson, Marc ^c,d,e  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Université Laval   (Canada)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cervical cancer; Human papillomavirus; Mathematical model; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; DRUG DOSE REGIMEN; FEMALE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTECTION; RISK; SCREENING; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE; VACCINATION; VIRUS TRANSMISSION; WART VIRUS;

CERVICAL CANCER; HUMAN PAPILLOMAVIRUS; MATHEMATICAL MODEL; VACCINATION;

ADOLESCENT; CANADA; CHILD; ENGLAND; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MODELS, BIOLOGICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS;

EID: 84900432256     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.098     Document Type: Article

References (22)

1. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012, 30(November (Suppl. 5)):F139-F148.
2. Dorleans F., Giambi C., Dematte L., Cotter S., Stefanoff P., Mereckiene J., et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010, 15(November (47)).
3. Centers for Disease Control and Prevention Noninfluenza vaccination coverage among adults - United States, 2011. MMWR Morb Mortal Wkly Rep 2013, 62(February):66-72.
4. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103(October (19)):1444-1451.
5. Safaeian M., Porras C., Pan Y., Kreimer A., Schiller J.T., Gonzalez P., et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013, 6(November (11)):1242-1250.
6. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs. 3 doses in young women: a randomized clinical trial. J Am Med Assoc 2013, 309(May (17)):1793-1802.
7. ® two-dose schedule receives European marketing authorisation 2014, http://www.gsk.com/media/press-releases/2013/gsk-cervarix--two-dose-schedule-receives-european-marketing-auth.html [accessed 27.03.14, Press release issued on 20 December 2013].
8. ®: New 2-dose schedule granted positive CHMP opinion for Europe's leading HPV vaccine 2014, http://www.spmsd.com/blog/2014/02/27/gardasil-new-2-dose-schedule-granted-positive-chmp-opinion-for-europes-leading-hpv-vaccine/ [accessed 27.03.14, Press release issued on 27 February 2014].
9. Joint Committee on Vaccination and Immunisation 11/12 February 2014: meeting minutes and agenda 2014, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/294834/JCVI.zip [accessed 27.03.14].
10. Kahn J.A., Bernstein D.I. HPV vaccination: too soon for 2 doses?. J Am Med Assoc 2013, 309(May (17)):1832-1834.
11. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. Br Med J 2008, 337:a769.
12. Jit M., Chapman R., Hughes O., Choi Y.H. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. Br Med J 2011, 343:d5775.
13. Brisson M., Van d V., De Wals P., Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007, 25(July (29)):5399-5408.
14. Brisson M., Laprise J.F., Drolet M., Van d V., Franco E.L., Kliewer E.V., et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine 2013.
15. Choi Y.H., Jit M., Gay N., Cox A., Garnett G.P., Edmunds W.J. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010, 28(May (24)):4091-4102.
16. Van de Velde N., Brisson M., Boily M.C. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010, 28(July (33)):5473-5484.
17. Wellings K., Nanchahal K., Macdowall W., McManus S., Erens B., Mercer C.H., et al. Sexual behaviour in Britain: early heterosexual experience. Lancet 2001, 358(December (9296)):1843-1850.
18. Garnett G.P., Anderson R.M. Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. IMA J Math Appl Med Biol 1994, 11(3):161-192.
19. Malagon T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012.
20. Statistics Canada Canadian Community Health Survey - Annual Component (CCHS). ; 2013 July 1. http://www23.statcan.gc.ca/imdb/p2SV.pl%3FFunction=getSurvey%26SDDS=3226%26Item_Id=50653%26lang=en.
21. Plummer M., Peto J., Franceschi S. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer 2012, 130(June (11)):2638-2644.
22. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccine 2011, 7(December (12)):1343-1358.